Corient Private Wealth LLC Sells 452 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Corient Private Wealth LLC decreased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 17.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,211 shares of the medical research company’s stock after selling 452 shares during the quarter. Corient Private Wealth LLC’s holdings in Bio-Rad Laboratories were worth $726,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BIO. Venturi Wealth Management LLC boosted its position in shares of Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 87 shares during the period. Picton Mahoney Asset Management raised its stake in Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $33,000. UMB Bank n.a. grew its position in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new position in shares of Bio-Rad Laboratories during the 4th quarter worth about $38,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Up 0.9 %

NYSE BIO opened at $247.65 on Friday. Bio-Rad Laboratories, Inc. has a 1-year low of $243.76 and a 1-year high of $387.99. The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of -3.81 and a beta of 0.98. The stock’s 50 day moving average is $295.53 and its two-hundred day moving average is $323.04. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BIO. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Finally, Wells Fargo & Company lowered their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and an average target price of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.